Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 versus sitagliptin versus placebo monotherapy in drug-naive type 2 diabetes
2009-016243-20Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c after 24 weeks of treatment. Started Jul 2010; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-016243-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016243-20.